Day: February 9, 2021

TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoidespatients advances to Stage 2 earlier than anticipatedCompany to initiate two new clinical trials to investigate lacutamab in peripheralT-cell lymphoma, including Phase 2 combination study with leading globallymphoma research network, LYSAWebcast featuring key opinion leaders today at 2:00 p.m. CET / 8:00 a.m. ETMARSEILLE, France, Feb. 09, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new clinical developments for its first-in-class, proprietary investigational asset, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. This includes advancement of the KIR3DL2-expressing mycosis fungoides (MF) cohort (cohort 2) to Stage...

Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) — TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipatedCompany to initiate two new clinical trials to investigate lacutamab in peripheral T-cell lymphoma, including Phase 2 combination study with leading global lymphoma research network, LYSAWebcast featuring key opinion leaders today at 2:00 p.m. CET / 8:00 a.m. ETInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new clinical developments for its first-in-class, proprietary investigational asset, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. This includes advancement of the KIR3DL2-expressing mycosis fungoides (MF) cohort (cohort 2) to Stage 2 in...

Marseille, 09 févr. 2021 (GLOBE NEWSWIRE) — Progression de l’essai TELLOMAK : la cohorte 2 de patients présentant un mycosis fongoïde exprimant KIR3DL2 avance au stade 2 plus tôt que prévuLa Société initie deux nouveaux essais cliniques pour évaluer lacutamab dans les lymphomes T périphériques, dont un essai de Phase 2 en combinaison en partenariat avec le groupe international de recherche sur les lymphomes, LYSAUne conférence avec des experts a lieu aujourd’hui à 14h00 CET / 8h00 ETInnate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui de nouvelles avancées dans le développement clinique de son produit expérimental propriétaire et « first-in-class », lacutamab. Lacutamab est un anticorps anti-KIR3DL2 en développement dans les lymphomes à cellules...

REGULATED INFORMATIONPreliminary documents for the Extraordinary General Meeting have been made available on company’s websiteGosselies, Belgium, 9 February 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholders’ meeting will be held on Friday 26 February 2021 as of 10am CET, at Bone Therapeutics’ registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium.The notice for the meeting, including the agenda of the day as well as the motions to vote, is published today in the Belgian Official Gazette and La Libre Belgique.The documents and preliminary information concerning this meeting are being made...

INFORMATION RÉGLEMENTÉEMise à disposition des documents préparatoires à l’Assemblée générale extraordinaire sur le site internet de la SociétéGosselies, Belgique, le 9 février 2021 à 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires innovantes répondant aux besoins médicaux non satisfaits en l’orthopédie et dans d’autres pathologies graves, informe ses actionnaires et les détenteurs de warrants et d’obligations convertibles de la Société qu’une assemblée générale extraordinaire se tiendra le vendredi 26 février 2021 à 10h00 CET au siège social de la société, rue Auguste Piccard 37, 6041 Gosselies, Belgique.La convocation de l’assemblée générale extraordinaire comportant l’ordre du jour et le texte des projets de résolutions est...

Polarcus Limited (in provisional liquidation) (“Polarcus” or the “Company”) (OSE: PLCS) refers to the announcements made on 26 January 2021 (Polarcus Addressing Long Term Financing Structure Following Financial Default and Polarcus: Notices Of Enforcement) and on 2 February 2021 (Polarcus: Lenders Withdraw Support Of Ongoing Vessel Operations). Capitalized terms in this announcement have the same meaning as given in those announcements.Throughout the above-referenced period, the Board has continued to have regard to the developing financial position of the Company, including the events of default that have occurred, the enforcement action which resulted in the Vessel-owning companies being transferred to a company controlled by the Lenders, and the Lenders confirming their withdrawal of continuing support of the Vessels’ operations....

Press ReleaseFebruary 9, 2021 – N° 3January 2021 P&C Renewal ResultsSCOR achieves excellent January 1, 2021, renewals,with +15.9% premium growthSCOR begins 2021 with excellent renewal results, in line with the forecasts shared during its September 2020 Investor day, when the company was amongst the first reinsurers to outline a very positive outlook for the P&C reinsurance market.Conditions for the Reinsurance treaty market hardened significantly, driven as anticipated by price increases and improved terms and conditions across all lines of business and all regions.SCOR took full advantage of these favorable market conditions, growing its Reinsurance treaty premium income up for renewal by 15.9% at constant exchange rates1. Premiums increased by EUR 472 million to EUR 3,445 million, with an overall average price increase...

Communiqué de presse9 février 2021 – N° 3Renouvellements P&C de janvier 2021SCOR enregistre d’excellents renouvellements au 1er janvier 2021, avec une croissance des primes de 15,9%SCOR commence l’année 2021 avec d’excellents renouvellements, conformes aux prévisions présentées lors de sa Journée Investisseurs en septembre 2020, où le Groupe fut l’un des tout premiers réassureurs à souligner les perspectives très favorables du marché de la (ré)assurance de dommages et de responsabilité.Les conditions de marché pour les traités de réassurance se sont nettement améliorées, portées, comme prévu, par des hausses tarifaires et une amélioration des termes et conditions pour l’ensemble des lignes d’affaires et l’ensemble des zones géographiques.SCOR a pleinement tiré parti de ces conditions de marché favorables, enregistrant une croissance...

New Delhi, India, 8th February 2021 – Qapita, a Singapore-based provider of digital equity management SaaS solutions, today announced that it has secured an undisclosed strategic investment from East Ventures. Qapita helps private companies and start-ups manage capitalisation tables (cap tables) and employee stock ownership plans (ESOPs). Qapita also aims to digitise issuance of equity awards and shares. The fresh round of funding will be used to further strengthen the team in Singapore, India and Indonesia, accelerate product development and build clientele. Qapita was founded in 2019 by CEO Ravi Ravulaparthi, COO Lakshman Gupta, and CTO Vamsee Mohan, who recognised the inefficiencies in private market ownership and transactions, coupled with the need to digitally disrupt this sector. The founders hold decades of experience in investment...